Metabolon Acquires Metabolomic Discoveries GmbH
News Sep 06, 2017
Metabolon, newly announced the acquisition of Metabolomic Discoveries GmbH, a leading metabolomics services and diagnostics company based near Berlin, Germany. Financial terms of the transaction were not disclosed.
“The acquisition of Metabolomic Discoveries builds on our vision to bring the value of metabolomics to regions around the globe as we continue to realize the promise of this unique and powerful technology,” said Metabolon CEO John Ryals, PhD. “This achievement acts as yet another proof point of our expansion and leadership in the metabolomics space, delivering new services and clinical products that improve health. The addition of Metabolomic Discoveries furthers our global expansion strategy and will provide us with greater access to the European market as we continue to innovate and grow.”
In addition to the acquisition of Metabolomic Discoveries, Metabolon has also established joint laboratory collaborations this year with organizations in China and the Middle East.
Nicolas Schauer, PhD, Metabolomic Discoveries’ managing director and co-founder, will join Metabolon’s executive team as managing director and continue to oversee laboratory operations in the German location.
“This is a great opportunity to combine our metabolomics expertise and approaches,” said Dr. Schauer. “Joining the leading metabolomics and biomarker company will enable us to offer new services and precision medicine products to a broader group of researchers and clinicians. I look forward to accelerating the metabolomics market in Europe with Metabolon.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE